Information Provided By: 
Fly News Breaks for April 28, 2017
EXAS
Apr 28, 2017 | 08:40 EDT
Roth Capital analyst Chris Lewis raised his price target for Exact Sciences to $33 from $26 after the company announced a "strong 1Q" beat across the board with volumes, ASPs, revenues, and gross margins all exceeding expectations. With USPSTF inclusion driving expanding reimbursement coverage, quality metrics inclusion driving physician adoption, and continued effective DTC initiatives, the analyst believes Exact Sciences is well-positioned to sustain "strong commercial momentum." He reiterates a Buy rating on the shares.
News For EXAS From the Last 2 Days
There are no results for your query EXAS
